Brigham and Women's Hospital
Harvard Medical School, Cardiology Division
Mark W. Feinberg
Dr. Mark W. Feinberg's research interests involve the identification of non-coding RNAs (microRNAs and lncRNAs) and transcription factors governing cellular differentiation and activation focusing on cell types that participate in the development of vascular disease states (endothelial cells, monocytes/macrophages, T cells, and smooth muscle cells). Our research interests broadly aim to identify and target: 1) anti-inflammatory signaling mediators in the development of atherosclerosis; and 2) angiogenic mediators involved in ischemic heart disease.
Our studies involve a number of cell types implicated in promoting vascular inflammation and impairing blood vessel growth, a process that may lead to heart attack, stroke, or peripheral artery disease. To date, we have identified: 1) specific transcription factors called Kruppel-like transcription factors (KLFs) (and ‘lead’ small molecule compounds targeting these factors); and 2) specific microRNAs and lncRNAs (small and large non-coding RNAs that regulate target gene expression) and have examined their effects on mouse models of vascular inflammation, atherosclerosis, and heart attack, in an effort to provide promising therapeutic strategies to ameliorate cardiovascular disease. These studies may allow for novel therapeutic strategies for treatment of inflammatory states such as atherosclerosis.
- Identification ncRNA (lncRNA, miRNA) using RNA-Seq
- Functional validation of ncRNA in vascular disease models in mice and endothelial cells by gain- and loss-of-function approaches
- Delivery strategies of targeting ncRNA to the vessel wall
- Mechanistic approaches for validating interactors
Interested in collaborating on
- Improved derivation of lncRNA interactors in vascular disease
- Validation of lncRNAs from human samples